Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 12 July 2018

 
 
 
   

New EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems

 
The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personalised medicine carried out by Charles River Associates on their behalf.

Personalised medicine is defined as “a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention”.

Read more


 
 
 
   

News

 

25062018 Apply now for the Health Collaboration Awards 2018
25 June 2018

Submit a project by 21 September 2018 Read more

 
 
 
   

Videos

 
A lifetime of breakthroughs
We were born to end patients’ suffering. To extend life and improve its quality. And right now, after decades of tireless... Read more

Fighting Cancer, For a Brighter Tomorrow
With over 1800 medicines in development we won’t rest until everyone affected by cancer sees a brighter tomorrow. Read more

 
 
 
   

Events

 

28052018 ITCC-P4 International Workshop: Improving pediatric oncology drug development through...
27 September 2018 (Amsterdam, The Netherlands)

The overarching goal is to streamline and improve the development of new oncology drugs for children and adolescents... Read more

War On Cancer Europe 2018
20 November 2018 (London)

The technological revolution and the future of patient engagement - A conference organised by The Economist Read more

 
 
 
   

We published

 

2018: The pharmaceutical industry in figures
28 June 2018 (Publications)

The Pharmaceutical Industry: a key asset to scientific and medical progress Read more

 
 
 
   

IMI PARADIGM Study

 
Survey to Find Out Stakeholders’ Needs and Expectations for Patient Engagement in the Medicines...
On 12 July 2018 (IMI Paradigm)

PARADIGM is working with all relevant stakeholders to improve the way patients they are involved in the medicines lifecycle... Read more